Literature DB >> 33341456

Possible immunity, inflammation, and oxidative stress mechanisms of Alzheimer's disease in COVID-19 patients.

Haili Wang1, Rongyin Qin2, Jun Zhang3, Yingzhu Chen4.   

Abstract

Entities:  

Year:  2020        PMID: 33341456      PMCID: PMC7718773          DOI: 10.1016/j.clineuro.2020.106414

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


× No keyword cloud information.
Dear Editors, We have read with great interest the paper from Alomari et al. [1] about the “COVID-19 and the Central Nervous System”. With the prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the risks of neurological disease need to be carefully evaluated for neurologists. We found the study very interesting and meaningful, because the authors found affected patients may be at high risk of developing Alzheimer's Disease (AD) after overcoming the COVID-19 infection. The study reported SARS-CoV-2 can disrupt angiotensin-converting enzyme type 2 (ACE2) signaling pathway, with a role of antioxidative stress and anti-neuroinflammation, cause neurodegeneration of dopaminergic neurons or impairment in cholinergic pathways, and may involve in the progression of AD. We highly agree with the authors opinions, are very interested in the AD related to SARS-CoV-2. Here, we want to contribute with some aspects related to AD caused by COVID-19 that may further support the hypothesis of the authors. First, COVID-19 is associated with a severe innate immune response [2]. As we all known, innate immune activation plays an critical role in AD pathophysiology [3]. Microglia is the brain’s major innate immune cells. The SARS-CoV-2 causes the activation of microglia, which produce the Chemokine C-C motif ligand (CCL) 2, and the increase of CCL 2 expression. Overexpression of CCL 2 induces massive increase in interleukin-6 and significant increase of pathogenic tau species, which may contribute to the pathogenesis of AD [3]. Next, SARS-CoV-2 may contribute to blood-brain barrier (BBB)-associated cognitive decline of AD. Endothelial dysfunction at the BBB can be caused by SARS-CoV-2 [4]. It is possible that circulating neurotoxins mediated by inflammatory factors enter the brain through the damaged BBB, which leads to neuronal loss and dysfunction and accelerates the process of developing into AD in the future [5]. Last but not the least, in retort to SARS-CoV-2, reactive oxygen species (ROS), an initiator of toxic innate immune responses, is overproduced. COVID-19 can induce excessive oxidative stress, an imbalance between the ROS and the antioxidant system, and alterations of redox balance in infected cells by altering mitochondrial function [6]. Oxidative stress can induce cell disfunction and cause neuronal death [6], which play an indispensable role in the pathobiology of AD through mitochondrial DNA disturbances including oxidative damage, mutations, and methylation shifts [7]. On the other hand, most people infected with SARS-CoV-2 are elderly, and AD is a age-related neurodegenerative disease. Aging is the most critical risk factor for AD [8]. It is well known that certain cognitive functions decline continuously with age. Continuous accumulation of mediated by ROS-mediated oxidative modifications is one of the potential mechanisms for COVID-19 to induce AD [9]. Consequently, in view of the present situation, the application of antioxidants is particularly necessary to take preventive measures for AD caused by SARS-CoV-2. Some antioxidants such as polyphenols, N-acetylcysteine, and resveratrol may hold a potential role of prevention free from AD caused by SARS-CoV-2 [9]. However, AD is a chronic disease and it takes a long process to develop clinical symptoms and confirm the diagnosis. In spite of this, it remains to be alerted to a possible increase in AD cases in COVID-19 survivors, and it is especially necessary to prevent it in advance.

Funding

There was no funding for this letter.

Availability of data and materials

No data were involved in this letter.

Authors’ contributions

Each author contributed to the writing of this letter. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethics approval was not necessary for this letter.

Consent for publication

We provide consent for publication.

Declaration of Competing Interest

The authors report no declarations of interest.
  9 in total

1.  Severe Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research.

Authors:  Mehmet Bostanciklioğlu
Journal:  Curr Neurovasc Res       Date:  2020       Impact factor: 1.990

Review 2.  Redox modifications in synaptic components as biomarkers of cognitive status, in brain aging and disease.

Authors:  Pablo Muñoz; Álvaro O Ardiles; Boris Pérez-Espinosa; Cristian Núñez-Espinosa; Andrea Paula-Lima; Christian González-Billault; Yolanda Espinosa-Parrilla
Journal:  Mech Ageing Dev       Date:  2020-05-17       Impact factor: 5.432

Review 3.  Potential role of endothelial cell surface ectopic redox complexes in COVID-19 disease pathogenesis.

Authors:  Isabella Panfoli
Journal:  Clin Med (Lond)       Date:  2020-06-29       Impact factor: 2.659

Review 4.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

Review 5.  Immediate and long-term consequences of COVID-19 infections for the development of neurological disease.

Authors:  Michael T Heneka; Douglas Golenbock; Eicke Latz; Dave Morgan; Robert Brown
Journal:  Alzheimers Res Ther       Date:  2020-06-04       Impact factor: 6.982

6.  CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy.

Authors:  Aurelie Joly-Amado; Jordan Hunter; Zainuddin Quadri; Frank Zamudio; Patricia V Rocha-Rangel; Deanna Chan; Anisha Kesarwani; Kevin Nash; Daniel C Lee; Dave Morgan; Marcia N Gordon; Maj-Linda B Selenica
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

Review 7.  Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration.

Authors:  Andrey Y Abramov; Elena V Potapova; Viktor V Dremin; Andrey V Dunaev
Journal:  Life (Basel)       Date:  2020-06-30

Review 8.  COVID-19 and the central nervous system.

Authors:  Safwan O Alomari; Zaki Abou-Mrad; Ali Bydon
Journal:  Clin Neurol Neurosurg       Date:  2020-08-04       Impact factor: 1.885

9.  Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease.

Authors:  Yoojin Shin; Se Hoon Choi; Eunhee Kim; Enjana Bylykbashi; Jeong Ah Kim; Seok Chung; Doo Yeon Kim; Roger D Kamm; Rudolph E Tanzi
Journal:  Adv Sci (Weinh)       Date:  2019-08-12       Impact factor: 16.806

  9 in total
  1 in total

Review 1.  Can SARS-CoV-2 Infection Exacerbate Alzheimer's Disease? An Overview of Shared Risk Factors and Pathogenetic Mechanisms.

Authors:  Chiara Villa; Eleonora Rivellini; Marialuisa Lavitrano; Romina Combi
Journal:  J Pers Med       Date:  2022-01-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.